1. DOSE‐DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH‐RISK DLBCL: A COMPARISON OF NORDIC CRY‐04 AND CHIC STUDIES. (June 2017) Authors: Leppä, S.; Joergensen, J.; de Nully Brown, P.; Fagerli, U.; Larsen, T.S.; Janes, R.; Mannisto, S.; Munksgaard, L.; Maisenhölder, M.; Vasala, K.; Meyer, P.; Jerkeman, M.; Björkholm, M.; Fluge, Ø.; Jyrkkiö, S.; Pedersen, L.M.; Eriksson, M.; Holte, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MORTALITY RATES REMAIN INCREASED IN YOUNG PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA EVEN AFTER YEARS IN REMISSION: RESULTS FROM A NORDIC LYMPHOMA GROUP STUDY. (June 2017) Authors: Biccler, J.; Glimelius, I.; Eloranta, S.; de Nully Brown, P.; Jakobsen, L.H.; Frederiksen, H.; Jerkeman, M.; Bøgsted, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OUTCOME PREDICTION IN DIFFUSE LARGE B‐CELL LYMPHOMA CAN BE GREATLY IMPROVED BY ALTERNATIVE USE OF CLINICAL INFORMATION: A NORDIC LYMPHOMA GROUP STUDY. (June 2017) Authors: Biccler, J.L.; Eloranta, S.; de Nully Brown, P.; Frederiksen, H.; Jerkeman, M.; Smedby, K.E.; Bøgsted, M.; El‐Galaly, T.C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL. (12th June 2019) Authors: Menter, T.; Tzankov, A.; Zucca, E.; Kimby, E.; Vanazzi, A.; Østenstad, B.; Mey, U.J.; Rauch, D.; Wahlin, B.; Hitz, F.; Hernberg, M.; Johansson, A.; de Nully Brown, P.; Hagberg, H.; Hawle, H.; Hayoz, S.; Dirnhofer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON‐NORDIC LYMPHOMA GROUP PHASE III STUDY. (12th June 2019) Authors: Lugtenburg, P.; de Nully Brown, P.; van der Holt, B.; d'Amore, F.; Koene, H.; de Jongh, E.; Fijnheer, R.; Loosveld, O.; Böhmer, L.; Pruijt, H.; Verhoef, G.; Hoogendoorn, M.; Bilgin, Y.; Nijland, M.; Lam, K.; de Keizer, B.; de Jong, D.; Zijlstra, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL. (12th June 2019) Authors: Nowakowski, G.; Willenbacher, W.; Greil, R.; Larsen, T.S.; Patel, K.; Jäger, U.; Manges, R.F.; Trümper, L.; Haioun, C.; Everaus, H.; Kalakonda, N.; Knoble, J.; de Nully Brown, P.; Jørgensen, J.M.; Cunningham, D.; Domper Rubio, N.; Casadebaig, M.; Manzke, O.; Munoz, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗